Biases may hit results of studies of cancer treatmentApril 21st, 2008 - 5:41 pm ICT by admin
Washington, April 21 (ANI): Observational studies comparing outcomes of different cancer therapies are susceptible to inaccuracies resulting from certain biases, according to a new study.
Dr. Sharon H. Giordano and her colleagues at the University of Texas MD Anderson Cancer Center in Houston set out to determine the accuracy of observational studies on cancer treatments, and compared the effectiveness of different cancer therapies in terms of prolonging survival in patients.
They used data from the SEER registry for the purpose.
In their first analysis, the researchers focussed their attention on a hormone therapy called androgen deprivation in men with stage III prostate cancer.
While randomised clinical trials showed that androgen deprivation could improve survival in patients, their analysis found that men treated with androgen deprivation actually had a higher risk of death from prostate cancer than men who did not receive the therapy.
Thereafter, the researchers re-analysed data from a previously published study of more than 43,000 men with localized prostate cancer who were treated compared with men who were not treated.
Just like the original study, the researchers analysis revealed that men who were treated for prostate cancer experienced lower mortality rates. They, however, found that in many cases, the cause of death was due to something other than prostate cancer, like diabetes or pneumonia.
The researchers then re-analysed data from a previously published study on the effects of fluorouracil-based chemotherapy for colon cancer, and came to the same conclusion as the original research studythat chemotherapy for node positive colon cancer is associated with improved survival.
However, their analysis also found that the link between the treatment and survival was strongest for non-cancer deaths, which presumably are not related.
The researchers said that the improbable results found in their three analyses were due to selection biases occurring when patients are treated.
They say that selection bias generally occurs when patients with poorer prognoses are more likely to receive a more efficacious drug, or when patients with better underlying health are more likely to receive a more toxic treatment because they are more likely to tolerate it.
The authors concluded: (The findings) suggest that the results of observational studies of treatment outcomes should be viewed with caution.
The findings appear in the journal CANCER. (ANI)
- Prostate cancer treatment 'ups risk of colorectal cancer' - Nov 16, 2010
- Surgery effective for aggressive prostate cancer patients - Sep 28, 2010
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- Hormone therapy 'doubles survival chances in men with prostate cancer' - Mar 25, 2011
- Gene fusion is the 'smoking gun' in the development of prostate cancer: Study - May 19, 2010
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
- Prostate cancer screening improves patients' quality of life - Oct 26, 2010
- Aspirin reduces risk of cancer recurrence in prostate cancer patients - May 03, 2011
- Aspirin use 'cuts risk of death from prostate cancer by more than half' - Oct 26, 2010
- 'Watchful waiting' often best strategy for low-risk prostate cancer - Jun 19, 2010
- Exercise improves survival in prostate cancer patients - Feb 02, 2012
- Australian scientists identify new way to treat prostate cancer - Feb 26, 2010
- 20-year-long study finds prostate cancer screening doesn't cut death risk - Apr 01, 2011
- This drug can reduce breast cancer recurrence - Sep 27, 2011
Tags: anderson cancer center, biases, cancer deaths, cancer therapies, cancer treatment, cancer treatments, colon cancer, giordano, hormone therapy, md anderson cancer, md anderson cancer center, mortality rates, observational studies, original research, prostate cancer, randomised clinical trials, seer, stage iii, texas md anderson, university of texas md anderson cancer center